Table 4.
Needling procedure performed during the study period and related variables. a
| ≤1 year | ≤2 years b | ≤3 years b | |
|---|---|---|---|
| All eyes, n (%) | 78 (36.8) | 89 (42.0) | 91 (42.9) |
| Total needling procedures, n | 115 | 145 | 163 |
| Antimetabolite/antifibrotic use, n (%) | |||
| Yes | 92 (80.0) | 117 (80.7) | 134 (82.2) |
| No | 23 (20.0) | 28 (19.3) | 29 (17.8) |
| Mean (SD) IOP, mmHg | |||
| Preneedling | 22.0 (7.5) | 22.2 (7.5) | 22.0 (7.4) |
| Postneedling | 15.4 (6.3) | 16.0 (6.8) | 16.4 (7.1) |
| Overall success rate, n/N (%) c | 38/103 (36.9) | 34/81 (42.0) | 29/60 (48.3) |
IOP = intraocular pressure, SD = standard deviation, SSI = glaucoma‐related secondary surgical intervention.
Safety population unless otherwise noted.
This analysis is cumulative and includes needlings performed up to months 24 and 36 of the study, respectively.
Overall success was defined as the sum of complete success and qualified success. Complete success was defined as ≥20% IOP reduction from medicated baseline without SSI, clinical hypotony (as defined in the Outcomes section) or topical IOP‐lowering medications, analysed in the effectiveness population. Qualified success was defined as ≥20% IOP reduction from medicated baseline without SSI or clinical hypotony while remaining on the same number or fewer topical IOP‐lowering medications, analysed in the effectiveness population, and did not include eyes that met the criteria for complete success.